Expression levels of haem oxygenase-1 in the omental adipose tissue and peripheral blood mononuclear cells of women with polycystic ovary syndrome.
暂无分享,去创建一个
Peng-Hui Wang | K. Seow | C. Juan | L. Ho | Yu-Hung Lin | Jiann‐Loung Hwang | Yi-Hsiu Lin | Yi-Hsiu Lin
[1] K. Seow,et al. Omental fat expression of adiponectin and adiponectin receptors in non-obese women with PCOS: a preliminary study. , 2009, Reproductive biomedicine online.
[2] B. Ludvik,et al. Diminished upregulation of visceral adipose heme oxygenase-1 correlates with waist-to-hip ratio and insulin resistance , 2009, International Journal of Obesity.
[3] J. Ndisang,et al. Upregulation of the heme oxygenase system ameliorates postprandial and fasting hyperglycemia in type 2 diabetes. , 2009, American journal of physiology. Endocrinology and metabolism.
[4] V. Positano,et al. Heme Oxygenase-1 Induction Remodels Adipose Tissue and Improves Insulin Sensitivity in Obesity-Induced Diabetic Rats , 2009, Hypertension.
[5] W. Aronow,et al. Treatment of Obese Diabetic Mice With a Heme Oxygenase Inducer Reduces Visceral and Subcutaneous Adiposity, Increases Adiponectin Levels, and Improves Insulin Sensitivity and Glucose Tolerance , 2008, Diabetes.
[6] N. Abraham,et al. Heme Oxygenase-Mediated Increases in Adiponectin Decrease Fat Content and Inflammatory Cytokines Tumor Necrosis Factor-α and Interleukin-6 in Zucker Rats and Reduce Adipogenesis in Human Mesenchymal Stem Cells , 2008, Journal of Pharmacology and Experimental Therapeutics.
[7] N. Abraham,et al. Pharmacological and Clinical Aspects of Heme Oxygenase , 2008, Pharmacological Reviews.
[8] A. Dokras,et al. Cardiovascular Disease Risk Factors in Polycystic Ovary Syndrome , 2008, Seminars in reproductive medicine.
[9] E. V. van Beek,et al. Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis. , 2007, The Journal of clinical endocrinology and metabolism.
[10] D. Neglia,et al. Beneficial effect of heme oxygenase-1 expression on myocardial ischemia-reperfusion involves an increase in adiponectin in mildly diabetic rats. , 2007, American journal of physiology. Heart and circulatory physiology.
[11] F. Bach,et al. Bilirubin and Biliverdin Treatment of Atherosclerotic Diseases , 2007, Cell cycle.
[12] Gerald F Watts,et al. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. , 2006, Atherosclerosis.
[13] F. Orio,et al. Endothelial dysfunction in PCOS: role of obesity and adipose hormones. , 2006, The American journal of medicine.
[14] W. Durante,et al. Metabolic syndrome increases endogenous carbon monoxide production to promote hypertension and endothelial dysfunction in obese Zucker rats. , 2006, American journal of physiology. Regulatory, integrative and comparative physiology.
[15] K. Schousboe,et al. Prevalence of endocrine diseases and abnormal glucose tolerance tests in 340 Caucasian premenopausal women with hirsutism as the referral diagnosis. , 2004, Fertility and sterility.
[16] K. Sutton-Tyrrell,et al. The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome. , 2004, The Journal of clinical endocrinology and metabolism.
[17] A. Pfeiffer,et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome , 2004 .
[18] D. Zander,et al. Heme oxygenase-1 expression in human lungs with cystic fibrosis and cytoprotective effects against Pseudomonas aeruginosa in vitro. , 2004, American journal of respiratory and critical care medicine.
[19] B. Kos-Kudła,et al. Serum adiponectin in women with polycystic ovarian syndrome and its relation to clinical, metabolic and endocrine parameters , 2004, Journal of endocrinological investigation.
[20] O. Zinder,et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. , 2004, The Journal of clinical endocrinology and metabolism.
[21] F. Orio,et al. Adiponectin levels in women with polycystic ovary syndrome. , 2003, The Journal of clinical endocrinology and metabolism.
[22] G. Villuendas,et al. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women , 2003, Diabetologia.
[23] V. Castracane,et al. Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: a comparison of two distinct populations. , 2002, American journal of obstetrics and gynecology.
[24] H. Lodish,et al. ACRP30, a new hormone controlling fat and glucose metabolism. , 2002, European journal of pharmacology.
[25] J. Ingwall,et al. Cardiac-Specific Expression of Heme Oxygenase-1 Protects Against Ischemia and Reperfusion Injury in Transgenic Mice , 2001, Circulation research.
[26] E. Diamanti-Kandarakis,et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. , 1999, The Journal of clinical endocrinology and metabolism.
[27] D. Langdon. A Fasting Glucose to Insulin Ratio Is a Useful Measure of Insulin Sensitivity in Women with Polycystic Ovary Syndrome , 1999 .
[28] Philipp E. Scherer,et al. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor , 1998, Current Biology.
[29] A. Dunaif,et al. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. , 1997, Endocrine reviews.
[30] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[31] Julia K Mader,et al. Adipose tissue, inflammation and cardiovascular disease. , 2010, Revista da Associacao Medica Brasileira.
[32] B. Fauser,et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). , 2004, Human reproduction.
[33] K. Seow,et al. Serum and adipocyte resistin in polycystic ovary syndrome with insulin resistance. , 2004, Human reproduction.
[34] W. Dodson,et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. , 1999, The Journal of clinical endocrinology and metabolism.